Yun-Yun He1, Wei Yan2, Chun-Lei Liu2, Xin Li2, Rui-Jun Li2, Yang Mu1, Qian Jia1, Fen-Fen Wu2, Li-Li Wang3, Kun-Lun He4. 1. Department of Cardiology, Chinese PLA General Hospital, Beijing China; School of Medicine, Nankai University, Tianjin China. 2. Department of Cardiology, Chinese PLA General Hospital, Beijing China. 3. Beijing Institute of Pharmacology and Toxicology, Beijing China. Electronic address: wangll63@126.com. 4. Department of Cardiology, Chinese PLA General Hospital, Beijing China. Electronic address: hekl301@aliyun.com.
Abstract
OBJECTIVES: S100A12 has been proposed as a novel pivotal factor in inflammation produced by granulocytes. The purpose of this study was to investigate the relationship between S100A12 and chronic heart failure (CHF). DESIGN AND METHODS: One hundred and seventy-seven patients with CHF and 66 subjects without CHF were included in this study. Plasma levels of S100A12 and high-sensitivity C-reactive protein (hs-CRP) were measured in all participants. After a follow-up period of 18months for CHF patients, major cardiovascular events (MCE), including cardiac death and rehospitalization for heart failure, were recorded. RESULTS: Plasma levels of S100A12 were significantly higher in CHF patients than in control subjects (P<0.001) and positively correlated with hs-CRP (r=0.316, P<0.001). S100A12 levels were also higher in MCE patients than in MCE-free patients. The occurrence of MCE increased with advancing plasma S100A12 levels by stratification according to quartiles (Q4 vs Q1, P=0.015). Cox proportional hazards regression analysis revealed that S100A12 was an independent risk factor for MCE in CHF patients (P=0.009). CONCLUSIONS: S100A12 is a potential biomarker of CHF that may provide important information regarding the prediction of MCE in patients with CHF.
OBJECTIVES:S100A12 has been proposed as a novel pivotal factor in inflammation produced by granulocytes. The purpose of this study was to investigate the relationship between S100A12 and chronic heart failure (CHF). DESIGN AND METHODS: One hundred and seventy-seven patients with CHF and 66 subjects without CHF were included in this study. Plasma levels of S100A12 and high-sensitivity C-reactive protein (hs-CRP) were measured in all participants. After a follow-up period of 18months for CHFpatients, major cardiovascular events (MCE), including cardiac death and rehospitalization for heart failure, were recorded. RESULTS: Plasma levels of S100A12 were significantly higher in CHFpatients than in control subjects (P<0.001) and positively correlated with hs-CRP (r=0.316, P<0.001). S100A12 levels were also higher in MCE patients than in MCE-free patients. The occurrence of MCE increased with advancing plasma S100A12 levels by stratification according to quartiles (Q4 vs Q1, P=0.015). Cox proportional hazards regression analysis revealed that S100A12 was an independent risk factor for MCE in CHFpatients (P=0.009). CONCLUSIONS:S100A12 is a potential biomarker of CHF that may provide important information regarding the prediction of MCE in patients with CHF.
Authors: Hu Zhai; Lei Huang; Yijie Gong; Yingwu Liu; Yu Wang; Bojiang Liu; Xiandong Li; Chunyan Peng; Tong Li Journal: Front Cardiovasc Med Date: 2022-06-01
Authors: Kira Trares; Megha Bhardwaj; Laura Perna; Hannah Stocker; Agnese Petrera; Stefanie M Hauck; Konrad Beyreuther; Hermann Brenner; Ben Schöttker Journal: Alzheimers Res Ther Date: 2022-09-09 Impact factor: 8.823